- GBI & PARTNERS
- AMEGI: Mexico’s domestic generic firms under pressure
AMEGI: Mexico’s domestic generic firms under pressure
The head of the Mexican Association of Generic Manufacturers (AMEGI), Rafael Maciel, has provided details of recent changes and pressures in Mexico’s generics market. According to AMEGI data, the generics sector currently accounts for 35%-40% of Mexico’s USD 16 billion market currently. However, there has recently been a fall in usage of generic drugs in private-sector independent pharmacies, which make up 56% of total generic drug retail outlets, with a fall in usage from 15% to 13% of the total.
There is also now considerable uncertainty surrounding domestic generics manufacturers, after the government indicated that it was open to the idea of displacing their products by purchasing from foreign generics manufacturers. The issue was one factor in the delay to the recent national drug tender, and also contributed to 62% of tenders not being filled. Maciel predicts that pharmacies will become a more frequent site for purchases of generic prescription drugs as a result of lack of stock in hospitals. He also revealed that Mexican firms are currently considering expansion internationally in order to counter escape competitive local conditions, including markets in Central and South America. Companies
Maciel explains that the industry is already working on innovations in the face of the new competition represented by laboratories that manufacture outside of Mexico, the drop in sales in independent pharmacies and the strong competition of generics in the country in general. Other firms are also considering moving into biosimilars development for markets in the United States, Canada, and Europe, according to Maciel.